Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Anthony V. Moorman; Amir Enshaei; Daniel Murdy; Melvin Joy; Judith M Boer; Monique L den Boer; Rob Pieters; Valerie De Haas; Martin A Horstmann; Gabriele Escherich; Bertil Johansson; Hanne Vibeke Marquart; Kjeld Schmiegelow; Jeremy Hancock; John Moppett; Mats Heyman; Monique den Boer

doi:10.1038/s41375-024-02329-0

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Anthony V. Moorman, Amir Enshaei, Daniel Murdy, Melvin Joy, Judith M Boer, Monique L den Boer, Rob Pieters, Valerie De Haas, Martin A Horstmann, Gabriele Escherich, Bertil Johansson, Hanne Vibeke Marquart, Kjeld Schmiegelow, Jeremy Hancock, John Moppett, Mats Heyman, Monique den Boer

Group den Boer

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

Originele taal-2	Engels
Pagina's (van-tot)	2023-2026
Aantal pagina's	4
Tijdschrift	Leukemia
Volume	38
Nummer van het tijdschrift	9
DOI's	https://doi.org/10.1038/s41375-024-02329-0
Status	Gepubliceerd - sep. 2024

Toegang tot document

10.1038/s41375-024-02329-0

Citeer dit

Moorman, A. V., Enshaei, A., Murdy, D., Joy, M., Boer, J. M., den Boer, M. L., Pieters, R., De Haas, V., Horstmann, M. A., Escherich, G., Johansson, B., Marquart, H. V., Schmiegelow, K., Hancock, J., Moppett, J., Heyman, M., & den Boer, M. (2024). Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. Leukemia, 38(9), 2023-2026. https://doi.org/10.1038/s41375-024-02329-0

@article{838e331ab2c34a9da418675e5436ab34,

title = "Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction",

keywords = "Humans, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics, Neoplasm, Residual/genetics, Male, Prognosis, Female, Adolescent, Child, Induction Chemotherapy, Adult",

author = "Moorman, {Anthony V.} and Amir Enshaei and Daniel Murdy and Melvin Joy and Boer, {Judith M} and {den Boer}, {Monique L} and Rob Pieters and {De Haas}, Valerie and Horstmann, {Martin A} and Gabriele Escherich and Bertil Johansson and Marquart, {Hanne Vibeke} and Kjeld Schmiegelow and Jeremy Hancock and John Moppett and Mats Heyman and {den Boer}, Monique",

year = "2024",

month = sep,

doi = "10.1038/s41375-024-02329-0",

language = "English",

volume = "38",

pages = "2023--2026",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "9",

}

Moorman, AV, Enshaei, A, Murdy, D, Joy, M, Boer, JM, den Boer, ML, Pieters, R, De Haas, V, Horstmann, MA, Escherich, G, Johansson, B, Marquart, HV, Schmiegelow, K, Hancock, J, Moppett, J, Heyman, M & den Boer, M 2024, 'Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction', Leukemia, vol. 38, nr. 9, blz. 2023-2026. https://doi.org/10.1038/s41375-024-02329-0

TY - JOUR

T1 - Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

AU - Moorman, Anthony V.

AU - Enshaei, Amir

AU - Murdy, Daniel

AU - Joy, Melvin

AU - Boer, Judith M

AU - den Boer, Monique L

AU - Pieters, Rob

AU - De Haas, Valerie

AU - Horstmann, Martin A

AU - Escherich, Gabriele

AU - Johansson, Bertil

AU - Marquart, Hanne Vibeke

AU - Schmiegelow, Kjeld

AU - Hancock, Jeremy

AU - Moppett, John

AU - Heyman, Mats

AU - den Boer, Monique

PY - 2024/9

Y1 - 2024/9

KW - Humans

KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics

KW - Neoplasm, Residual/genetics

KW - Male

KW - Prognosis

KW - Female

KW - Adolescent

KW - Child

KW - Induction Chemotherapy

KW - Adult

U2 - 10.1038/s41375-024-02329-0

DO - 10.1038/s41375-024-02329-0

M3 - Article

C2 - 38965371

SN - 0887-6924

VL - 38

SP - 2023

EP - 2026

JO - Leukemia

JF - Leukemia

IS - 9

ER -